SORCIN与肿瘤耐药及耐药相关转运体研究进展  

Advances in the study of SORCIN in cancer drug resistance

作　　者：孙耀庭[1] 刘克辛[1] SUN Yao-ting LIU Ke-xin(College of Pharmacy, Dalian Medical University, Dalian 116044, China)

机构地区：[1]大连医科大学药学院,辽宁大连116044

出　　处：《药学学报》2017年第9期1372-1378,共7页Acta Pharmaceutica Sinica

基　　金：国家自然科学基金资助项目(81473280)

摘　　要：可溶性耐药相关钙结合蛋白(soluble resistance-related calcium-binding protein,SORCIN)是一个22k Da的具有典型"EF-hand"结构的钙结合蛋白,参与细胞内钙稳态调节。SORCIN广泛分布于多种组织,其中在正常的心脏与脑组织中高表达,而在部分肿瘤组织中过表达。近年来,大量的临床数据显示SORCIN与肿瘤耐药性密切相关。基础研究表明SORCIN不仅参与肿瘤细胞多药耐药(multidrug resistance,MDR)的形成,且与肿瘤的恶性程度、不良预后密切相关。此外,部分研究证明SORCIN参与ATP结合盒转运体(ABC transporter)的调节,进而对肿瘤耐药性产生影响。因此,SORCIN有望成为肿瘤耐药诊断及治疗的新靶点。本文对SORCIN及其在肿瘤耐药方面的研究进展进行综述。Soluble resistance-related calcium-binding protein, SORCIN, is a 22 k Da calcium binding protein with ＂penta-EF hand＂, which participates in the regulation of intracellular calcium homeostasis in cells. SORCIN is highly expressed in many tissues such as hearts and brains. It is overexpressed in some of cancer tissues as well. Recently, a large amount of clinical data showed that SORCIN was closely related to drug resistance in cancer. Meanwhile, basic research found that SORCIN participates in the formation of multidrug resistance（MDR） and is related to severity and poor prognosis of tumors. Moreover, it may also regulate MDR induced by ATP-binding cassette transporters. Therefore, SORCIN is expected to become a new target for diagnosis and treatment of MDR. The present review summarizes recent progress in SORCIN study and its effect on MDR.

关 键 词：可溶性耐药相关钙结合蛋白 多药耐药 ATP结合盒转运体 P-糖蛋白 钙稳态 

分 类 号：R963[医药卫生—微生物与生化药学]